Trimetazidine and Bisoprolol to Treat Angina in Symptomatic Patients: Post Hoc Analysis From the CHOICE-2 Study
| العنوان: | Trimetazidine and Bisoprolol to Treat Angina in Symptomatic Patients: Post Hoc Analysis From the CHOICE-2 Study |
|---|---|
| المؤلفون: | M G Glezer |
| المصدر: | Cardiology and Therapy |
| بيانات النشر: | Springer Science and Business Media LLC, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | medicine.medical_specialty, Combination therapy, Trimetazidine, Hemodynamics, 030204 cardiovascular system & hematology, Angina, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Post-hoc analysis, medicine, Bisoprolol, 030212 general & internal medicine, Original Research, Cause of death, business.industry, Canadian Cardiovascular Society, medicine.disease, Cardiology, Real-world clinical setting, Cardiology and Cardiovascular Medicine, business, medicine.drug |
| الوصف: | Introduction Angina is the cardinal symptom of chronic coronary syndrome (CCS), which is the leading cause of death worldwide. As such, the control of angina is important. The current guidelines recommend beta blockers (BB) or calcium channel blockers to reduce angina, yet many patients with stable angina remain symptomatic. It has been suggested that combining trimetazidine (TMZ), an anti-ischemic agent, with a BB is beneficial for symptomatic patients. Bisoprolol, a BB, is often used to treat patients with CCS, yet no data are currently available regarding the efficacy of bisoprolol combined with TMZ in patients who remain symptomatic despite receiving bisoprolol. Methods The aim of this post-hoc analysis of the CHOICE-2 study was to evaluate the efficacy and safety of TMZ 35 mg twice daily in combination with different bisoprolol doses in symptomatic patients with stable angina patients receiving hemodynamic therapy in a real-world clinical setting. Results This analysis involved 221 patients (mean [± standard deviation] age 64.8 ± 8.9 years) with stable angina. The mean number of weekly angina episodes gradually fell from 6.2 ± 5.3 at inclusion (M0) to 1.5 ± 1.9 at 6 months after treatment initiation (M6) with combined TMZ–bisoprolol therapy (P |
| تدمد: | 2193-6544 2193-8261 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f2150e054c5ead947735925c2ee208eTest https://doi.org/10.1007/s40119-020-00202-6Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....3f2150e054c5ead947735925c2ee208e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 21936544 21938261 |
|---|